Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed. Semaglutide for Weight Loss, Ivermectin for Mild #COVID19, USPSTF Guideline on Screening for Vitamin D Deficiency, and more. Anne Cappola, MD, Associate Editor of JAMA, summarizes the April 13, 2021, issue. Can amylin weight loss drugs compete in a world of GLP 1s? C&EN Global Enterprise